Patients with renal cell carcinoma (RCC) can have an acceptable long-term survival following radical nephrectomy and venous thrombectomy (RN-VT), according to a recent study.

In addition, investigators identified prognostic factors for cancer-specific survival (CSS).

The study included 270 patients with RCC and venous thrombus. After a median follow-up of 31 months, 85 patients (31.5%) died, 60 (22.2%) from RCC, Yu Zhang, MD, of Peking University Third Hospital in Beijing, China, and colleagues reported in the Journal of Oncology. The 1- and 3-year CSS rates were 89.3% and 72.7%, respectively. Median overall survival (OS) was 56 months. The 1-, 3-, and 5-year OS rates were 87.0%, 62.1%, and 44.8%, respectively.


Continue Reading

The investigators also examined outcomes by metastasis status. For patients with metastatic disease, median OS was 27.0 months. The 1-, 3-, and 5-year OS rates were 78.0%, 41.5%, and 23.3%, respectively. For patients without metastases, the median recurrence-free survival (RFS) was 38.0 months; the 1- and 3-year RFS rates were 81.2% and 52.3%, respectively.

In addition, the study demonstrated that papillary pathology, perinephric fat invasion, sarcomatoid differentiation, and distant metastasis predicted an elevated risk for cancer-related death. On multivariable analysis, papillary RCC was significantly associated with a nearly 3-fold increased risk for cancer-related death compared with clear cell RCC. Perinephric fat invasion and sarcomatoid differentiation were significantly associated with a 1.5- and 2.9-fold increased risk for cancer-related death, respectively, compared with the absence of these features. Patients with distant metastasis had a 1.8-fold increased risk for cancer-related death compared with patients without nodal involvement or distant metastasis.

Reference

Zhang Y, Tian XJ, Bi H et al. Oncologic outcomes of renal cell carcinoma patients undergoing radical nephrectomy and venous thrombectomy: Prospective follow-up from a single-center. J Oncol. Published online March 17, 2022. doi:10.1155/2022/9191659

This article originally appeared on Renal and Urology News